Medication Reviews ReDirected (MedReDi): Acute Coronary Syndrome as an Indication for Home Medicine Review, a Randomised Controlled Trial
Suspended
- Conditions
- Secondary prevention of acute coronary syndromeCardiovascular - Coronary heart diseasePublic Health - Health service research
- Registration Number
- ACTRN12611000452998
- Lead Sponsor
- nit for Medication Outcomes Research and Education, School of Pharmacy, University of Tasmania, Sandy Bay
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 465
Inclusion Criteria
Any patients admited with a diagnosis of acute coronary syndrome or equivalent event, including: unstable angina, non-ST elevation AMI, ST elevation AMI, AMI, or heart attack.
Exclusion Criteria
Cognitive decline to the extent that it may prevent ability to obtain informed consent directly from the patient. Palliative patients with a life expectancy less than 18 months. Discharge destination other than home. Non-Medicare eligible patients, eg. international patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients taking all four classes of Australian National Heart Foundation guideline-recommended medications at six and twelve months post-discharge from an acute coronary syndrome hospital admission. The four medication classes include: antithrombotics (aspirin/clopidogrel/prasugrel); ACE inhibitors or ARB's; beta blockers; statins. The Medication Possession Ratio (MPR) assessed by collecting community pharmacy dispensing records will be the primary measure for this outcome with an MPR of 80 to 120% accepted as the adherence cut-offs. The Morisky Questionnaire will be the secondary measure if MPR recrods are incomplete.[Six and twelve months post-discharge for an acute coronary syndrome hospital admission.]
- Secondary Outcome Measures
Name Time Method